Assemblée annuelle 2009
Date:
|
13 –15 mai 2009
|
| Lieu: |
Bâle – Congress Center |
Inscription, informations et détails: sous www.congress-info.ch/sgim2009
Aperçu du programme
| Jeudi, 14 mai 2009 |
| |
12h30 – 13h30
|
Assemblée générale SSH
|
| |
Symposium SSH, 1ère partie
Myeloproliferative Neoplasms in 2009
Chairpersons: André Tichelli, Basel / Andreas Tobler, Bern
|
| 14h00–14h30 |
The molecular pathogenesis of myeloproliferative disorders
Radek Skoda, Basel
|
14h30–15h00
|
20 years of Interferon therapy for Ph-negative myeloproliferative disorders: from hematological to molecular response
Jean-Jacques Kiladjian, Bobigny FR
|
15h00 – 15h45
|
Presidential Symposium SGH
|
| |
Discours des lauréats
Prix de l’hématologie clinique
Abstract No 1 SSH
Jakob Passweg, Genève
Prix de l’hématologie expérimentale
Abstract No 2 SSH
Nicolas Bonadies, Cambridge GB
Remise du prix hémostase Roche et discours du lauréat
|
| |
Symposium SSH, 2ème partie
Iron and Anemia
Chairpersons: Jean-Philippe Grob, Lausanne / Ulrich Buser, Basel
|
| 16h15–16h45 |
Iron deficiency anemia in the light of recent findings in iron metabolism
Photis Beris, Genève
|
| 16h45–17h15 |
Anemia of chronic disease
Sigismond Lasocki, Paris FR
|
| 17h15–17h45 |
Anemia in the elderly
Elizabeth A. Price, Palo Alto US
|
dès 20h00
|
Soirée sociale SSH
|
| Vendredi, 15 mai 2009 |
| |
| |
Communications libres SSH session 1
|
| 8h45 – 10h45
|
Experimental Hematology
Chairpersons: Olivier Spertini, Lausanne / Martin Fey, Bern
|
| FM40 |
Donor T Cell Production of IL-21 Accelerates Graft-Versus-Host Disease Lethality
Bucher C., Vogtenhuber C., Jasperson L., Goren E., Panoskaltsis-Mortari A., Sivakumar P., Blazar B. (Minneapolis, Seattle)
|
| FM41 |
Large-scale clinical grade expansion of alloreactive
haploidentical natural killer cells for multiple infusions to leukemia
patients
Siegler U., Meyer-Monard S., Jörger S., Stern M., Tichelli A., Gratwohl A., Wodnar-Filipowicz A. (Basel)
|
| FM42 |
Involvement of microRNAs in post-transcriptional regulation of NKG2D ligand expression in human tumor cell lines
Himmelreich H., Mathys A., Wodnar-Filipowicz A., Kalberer C. (Basel)
|
| FM43 |
HUMAN EMBRYONIC STEM CELLS DIFFERENTIATED IN ABSENCE OF XENOGENIC
COMPOUNDS GENERATE CD34+ AND CD34- HEMATOPOIETIC CELLS WITH DISTINCT
PROGENITOR CHARACTERISTICS
Chicha L., Jaconi M., Passweg J., Kindler V. ( Geneva)
|
| FM44 |
Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as essential regulator of SDF1α/CXCR4-mediated homing and migration
Schwaller J., Brault L., Grundler R., Gasser C., Bullock A., Ehret S., Woetzel S., Berridge G., Spoo A., Dierks C., Biondi A., Knapp S., Schwaller J. (Basel, München, Oxford, Freiburg/Breisgau, Monza)
|
| FM45 |
The fusion protein PML-RARA suppresses the master transcription factor PU.1 by targeting the chaperone protein calreticulin.
Vallabhapurapu D., Christen E., Petkovic V., Schardt J., Pabst T., Mueller B.U. (Bern)
|
| FM46 |
Protein disulfide isomerase (PDI) is upregulated during the unfolded protein response and blocks CEBPA mRNA translation in leukemic cells.
Pabst T., Haefliger S., Eyholzer M., Timchenko N., Mueller B., Pabst T. (Bern, Houston,TX)
|
| FM47 |
Myeloid differentiation of leukemic cells critically depends on autophagy
Britschgi A., Yousefi S., Simon H.U., Tobler A., Fey M.F., Tschan M.P. (Bern)
|
| FM48 |
A MOUSE MODEL FOR TESTING THE EFFICACY OF JAK2 INHIBITORS
Kubovcakova L., Hao-Shen H., Looser R., Pianta A., Schaub F., Lundberg P., Skoda R.C. (4031, Basel)
|
| FM49 |
Disruption of GAS6-MER Pathway Leads to Defects in Physiological Clearance of Expelled Nuclei from Erythroblasts by Bone Marrow Macrophages
Kadi l., Burnier L., Rocco S., Carmeliet P., Lemke G., Earp S., Matsushima G., Schapira M. (Lausanne, Belgium, USA
|
| |
Communications libres SSH session 2
|
| 11h15 – 12h45 |
Hemostasis, Vascular Biology and Transfusion Medicine
Chairpersons: Behrouz Mansouri, Bern / Anne Angelillo-Scherrer, Lausanne
|
FM50
|
Erythrocytes from hyperlipemic donors have a higher rate of hemolysis after storage
Schulzki T., Reinhart W. (Chur)
|
| FM51 |
Diagnostic value of platelet flow-cytometric analysis in patients with clinically relevant bleeding diathesis and unrevealing laboratory work-up
Alberio L., Conte T., Pavicic M., Reusser M., Barizzi G., Keller P. (Bern)
|
| FM52 |
Vinorelbine and Pegfilgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Multiple Myeloma: A Predictive and Cost Effective Procedure
Bargetzi M., Pabst T., Schoenenberger A., Burger J., Fernandez P., Moosmann P., Mansouri B., Huber A., Baerlocher G., Wernli M., Heizmann M. (Aarau, Bern)
|
FM53
|
Massively Reduced Arachidonic Acid in Red Cell Membranes and in Adipose Tissues with a Diet Rich in Alpha-Linolenic Acid which Diminishes Atherosclerosis in Apolipoprotein E-Deficient Mice
Beer J.H., Matter C., Lohmann , Richter , Leiber , Tanner F., Lüscher T. (Baden, Zürich)
|
| FM54 |
The Gain of Function Platelet Polymorphism of GPIb alpha (5T/C) is Overrepresented in Smokers with Symptomatic Carotid Stenosis: An Exploratory Study
Beer J.H., Lugli-Kopp , Brown M., Steffel , Büchi , Spleiss , Förnzler , Dupont , Gaussem , Forestier (Baden, London, Basel, Paris)
|
| FM55 |
Klinische Fassetten des hereditären Angioödems (HAE) bei einem Schweizer Patientenkollektiv
Wuillemin W.A., Wuillemin W.A. (Luzern)
|
| FM56 |
GENERATION AND PHENOTYPIC ANALYSIS OF PROTEIN S-DEFICIENT MICE
Saller F., Brisset A.C., Azevedo M., Chrast R., Schapira M., Griffin J.H., Angelillo-Scherrer A. (Lausanne, Service and Central Laboratory of Hematology, CHUV, Lausanne, Department of Medical Genetics, UNIL, Lausanne, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, USA)
|
| FM57 |
Pharmacokinetics of dalteparin in therapeutic dosage in patients with renal insufficiency
Schmid P., Brodmann D., Odermatt Y., Fischer A.G., Wuillemin W.A. (Luzern)
|
| FM58 |
Congenital or acquired ADAMTS13 deficiency or both – that’s the question.
Meyer S.C., Sulzer I., Mäder G., George J.N., Lämmle B., Kremer Hovinga J.A. (Bern, Oklahoma City)
|
| |
Communications libres SSH session 3 |
14h00 – 16h30
|
Clinical Hematology
Chairpersons: Jakob Passweg, Genève / Urs Schanz, Zürich
|
FM59
|
25 years of stem cell transplantation in Geneva. Impact of immunotherapy using donor derived T-cells. Review and Outlook
Chalandon Y., Roosnek E., Helg C., Kindler V., Huguet S., Mohty B., Mach-Pascual S., Ansari M., Tiercy J.M., Miralbell R., Chapuis B., Passweg J. (Genève)
|
| FM60 |
Late Altered Organ Function in Long Term Survivors after Allogeneic HSCT: A Paired Comparison with their Identical Sibling Donor.
Rovo A., Daikeler T., Halter J., Heim D., Studt J.D., lMedinger M., Arber C., Stern M., Tsakiris D., Tyndall A., Gratwohl A., Tichelli A. (Basel)
|
FM61
|
“Late altered immunity” a distinct entity in long term survivors after allogeneic HSCT?
Rovo A., Daikeler T., Halter J., Heijnen I., Heim D., Arber C., Tyndall A., Gratwohl A., Tichelli A. (Basel)
|
| FM62 |
Severe immune hemolysis and pure red cell aplasia after haploidentical nonmyeloablative allogeneic stem cell transplantation
Nair G., Mischo A., Stussi G., Schanz U. (Zürich)
|
| FM63 |
Rituximab for chronic Graft-versus-host disease
Nair G., Schanz U., Stussi G. (Zürich)
|
| FM64 |
THE ABUNDANT CD56bright NK-CELL POPULATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) ARE CYTOKINE ACTIVATED- RATHER THAN IMMATURE NATURAL KILLER CELLS
Vukicevic M., Chalandon Y., Helg C., Matthes T., Dantin C., Huard B., Passweg J., Roosnek E. (Genève)
|
| FM65 |
Prospective registration and follow up of donors of allogeneic hematopoietic stem cells (HSC) in a common protocol for related and unrelated donors: experience of the first 18 month
Halter J., Nicoloso-de Faveri G., Buhrfeind E., Baldomero H., Chalandon Y., Huguet S., Stüssi G., Güngör T., Seger , Passweg J., Schanz U., Gratwohl A. (Basel, Bern, Genève, Zürich)
|
| FM66 |
First Results of the GRAAPH-2005 Study in younger Adult Patients with De Novo Philadelphia Positive Acute Lymphoblastic Leukemia
Chalandon Y., Thomas X., Hayette S., Cayuela J.M., Abbal C., Escoffre-Barbe M., Maury S., Lepretre S., Witz F., Malfuson J.V., Leguay T., Buzyn A., Dombret H. (Genève, GRAALL group Lyon France, GRAAL group Lyon France, Hôptital Saint Louis, Paris, France, CHUV, Lausanne, Hôpital Ponchaillou, Rennes, GRAAL group, Lyon, France, Hôpitaux de Brabois, Nancy, France, CHU de Bordeaux, France)
|
| FM67 |
Investigating acute leukemias with gene expression arrays in a routine setting: a pilot study from the Geneva University Hospital
Matthes T., Rossier M., Rebsamen M., Chiappe A., Diemand A., Schindela S., Johnson A., Liu W.m., Wieczorek L., Haferlach T., Kohlmann A. (Genève, Munich, Pleasanton)
|
| FM68 |
Acute lymphoblastic leukemia in childhood: proliferation at different stages of immunophenotypic maturation
Hirt A., Schmid A.M., Leibundgut K. (Bern)
|
| FM69 |
Platelet transfusion threshold for central venous catheter insertion in patients with hematological malignancies
Zeidler K., Arn K., Senn O., Schanz U., Stüssi G. (Münsterlingen, Zürich)
|
| FM70 |
Divisional Heterogeneity in Long-Term Hematopoietic Stem Cells
Takizawa H., Boddupalli S., Manz M. (Bellinzona)
|
| FM71 |
Increased somatic mutation rate in hematopoietic cells from MPD patients is detectable prior to the acquisition of the JAK2-V617F mutation
Lundberg P., Skoda R., Rischewski J., Tichelli A. (Basel)
|
| FM72 |
The first case of IRIDA in Switzerland: characterisation of two novel mutations and successful treatment by continuous i.v. iron infusion.
Tchou I., Diepold M., Villard J., Swinkels D., Neerman-Arbez M., Beris P. (Dep. of Internal Medicine, HUG, Geneva, Pediatric Clinic, Bern Univ. Hospital, Radboud Universiteit Nijmegen, NL, Medical Genetics, CMU-Geneva)
|
|